Advertisement

NLS xbrane

Acquisition - February 18, 2022

Xbrane pauses negotiations with expected acquirer of Primm Pharma

Xbrane Biopharma’s efforts to divest the subsidiary Primm Pharma continues although negotiations with the previously expected acquirer NewFaDem for the time being has been paused. Primm Pharma is a fully owned subsidiary of Xbrane specialized in long-acting injectables and developer of Spherotide, a long-acting triptorelin formulation candidate intended to be used in treatment of prostate […]

Agreement - February 8, 2022

Xbrane Biopharma enters agreement with Biogen

The two companies have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA. CIMZIA’s primary indication is for rheumatoid arthritis in adults as well as axial spondylarthrosis, psoriasis and Crohn’s disease. In 2020 global sales of CIMZIA were 1.8 billion […]

Agreement - October 7, 2021

Xbrane Biopharma enters agreement with AGC Biologics

Xbrane Biopharma and AGC Biologics, a global Biopharmaceutical CDMO, have entered into an agreement to manufacture Xcimzane, a Cimzia biosimilar candidate, for clinical development. Under terms of the agreement, the companies will work together to upscale the established Xcimzane manufacturing process and produce several commercial scale batches for upcoming phase I and phase III clinical […]

Clinical Trials - June 30, 2021

Xbrane’s Xlucane meets primary endpoint

Xbrane Biopharma has announced results from the six months interim read-out in the Phase III equivalence trial with the Lucentis biosimilar candidate Xlucane. Xlucane met the primary endpoint demonstrating equivalent efficacy in change of BCVA (Best Corrected Visual Acuity) at week 8 of treatment compared to Lucentis, states the company in a press release. Xbrane […]

Biotech Business - May 21, 2020

Xbrane raises 146 million SEK

The Board of Directors of Xbrane Biopharma has successfully completed a directed issue of 3,853,799 shares corresponding to approximately SEK 146 million before costs related to the transaction. The subscription price in the Directed Share Issue has been determined to 38 SEK per share through an accelerated book building procedure performed by Vator Securities AB. […]

Biotech Business - September 17, 2019

Xbrane to list on Nasdaq Stockholm

Nasdaq Stockholm’s listing committee has decided that Xbrane Biopharma AB fulfills the requirements for admission to trading of the company’s shares on the main market Nasdaq Stockholm. The first day of trading of Xbrane’s shares on Nasdaq Stockholm is expected to be Monday 23 September 2019. The last day of trading of Xbrane’s shares on […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.